US Executive Officer Management Changes SEC — October 28, 2026

28-10-2026

GE HealthCare reported Q3 2026 revenue of $5.5 billion, up 7.2% (6.2% organic), with net income attributable to GE HealthCare rising to $615 million from $446 million and diluted EPS of $1.36 versus $0.98. Adjusted EBIT margin expanded 180 bps to 16.6%, and full-year 2026 guidance was raised for organic revenue growth, Adjusted EBIT margin, Adjusted EPS, and free cash flow. Growth was not uniform: PCS segment EBIT margin of 8.6% remains well below AIS (15.3%) and PDx (29.9%), and the company announced the departure of PCS President and CEO Jeannette Bankes effective with Neal Sandy's appointment on November 16, 2026, alongside a planned $945 million cash acquisition of SOFIE Biosciences.

• · Q3 2026 Adjusted EBIT margin of 16.6% rose 180 bps YoY, driven by volume, price, cost productivity and favorable net tariff impact, partially offset by inflation
• · Q3 2026 operating cash flow and free cash flow both include a $55M tariff refund
• · PCS segment EBIT margin of 8.6% remains the lowest of the three segments despite 480 bps of YoY improvement
• · PCS segment organic revenue growth was 8.8%, while AIS organic growth was 4.5% and PDx organic growth was 13.8%
• · Full-year 2026 Adjusted EPS guidance raised to $4.95–$5.05 from $4.80–$5.00, representing 7.9%–10.1% growth versus 2025A
• · Full-year 2026 organic revenue growth guidance updated to approximately 4.0% from a prior range of 3.0%–4.0%
• · Full-year 2026 Adjusted EBIT margin guidance raised to 15.5%–15.7% from 15.4%–15.7%
• · Free cash flow guidance raised to $1.6B+ from approximately $1.6B
• · Quarterly dividend increased 14% to $0.04 per share
• · Year-to-date 2026 operating cash flow of $1,365M and free cash flow growth were supported by inventory build of $430M and a $2,293M cash outlay on business acquisitions
• · Total debt rose to $10.0B from $9.5B long-term plus $0.5B short-term at December 31, 2025, and cash fell to $2.9B from $4.5B
• · Backlog of $23.7B and book-to-bill of 1.03x indicate orders modestly exceeded revenue in the quarter
• · SOFIE acquisition expected to close in first half of 2027 subject to regulatory approvals; establishes U.S. PET radiopharmaceutical 'final mile' footprint

28-10-2026

Enanta Pharmaceuticals announced that CEO Jay R. Luly, Ph.D. (age 70) will retire by February 1, 2027, after 23 years of leadership, and will serve as a Strategic Advisor through the remainder of 2027. The company simultaneously appointed Tara L. Kieffer, Ph.D. to the newly created role of Chief Operating Officer, and the Board has launched a comprehensive search for a successor. The transition is a leadership change with no quantitative financial results disclosed.

• · CEO retirement effective no later than February 1, 2027
• · Dr. Luly remains as Strategic Advisor for the remainder of 2027 to support transition
• · Chief Operating Officer role is newly created and will drive operational execution and alignment with strategic priorities
• · Board is considering both internal and external candidates for CEO successor
• · Enanta's HCV royalties from AbbVie-partnered glecaprevir products contribute ongoing operational funding
• · Pipeline includes RSV programs and immunology programs targeting KIT, STAT6 and MRGPRX2 inhibition
• · Forward-looking risks cited include need to attract and retain senior management and key R&D personnel

28-10-2026

Mitesco, Inc. (OTCQB: MITI) appointed Frank Panunto to its Board of Directors effective October 25, 2026. Panunto has advised the company for nearly two years on its Robo Agent application development project and brings three decades of franchise turnaround and real estate experience, currently serving as Vice President of Growth, U.S. East, at eXp Realty. The filing is a board appointment with no quantitative financial results disclosed.

• · Panunto previously served as Branch Manager of Long & Foster Real Estate's Bear, Delaware office from 2014 to 2023
• · Panunto earned a bachelor's degree in architectural design from the University of Delaware in 1991
• · Forward-looking statements reference a potential proposed spinout and dividend distribution, and a restructuring of Series A preferred stock and bridge notes, without further detail in this exhibit

28-10-2026

Red Robin Gourmet Burgers (NASDAQ: RRGB) announced that directors James Pappas (Managing Member of JCP Investment Management) and Chris Martin (Managing Director of Jumana Capital) resigned from the Board effective October 23, 2026, reducing the Board to six directors, five of whom will be independent. The company cited substantial completion of its refranchising program (more than 100 Company-operated restaurants sold) and a refinancing of its prior credit agreement into a new five-year, $115 million senior secured facility led by JPMorgan Chase Bank, N.A. (a $90 million term loan and a $25 million revolver), which carries lower borrowing costs. The filing does not disclose any operating decline, though the company's forward-looking statements flag risks including integration of the transactions, debt service, covenant compliance, and potential contingent lease liabilities.

• · Resignations were effective October 23, 2026, though the announcement was dated October 27, 2026, and the 8-K was filed October 28, 2026.
• · Pappas and Martin joined the Board in December 2024 in connection with an additional investment by Jumana and JCP.
• · The new facility carries a five-year term and is described as having meaningfully lower borrowing costs than the prior agreement; specific interest rates and the prior facility size are not disclosed.
• · The company's forward-looking statements explicitly flag risks including possible failure to fully realize refranchising and refinancing benefits, debt service and covenant compliance, potential contingent lease liability, and geographic concentration in the Western US.

28-10-2026

HF Sinclair reported Q3 2026 net income attributable to stockholders of $2,015 million ($11.38 per diluted share), versus $403 million ($2.15 per diluted share) in Q3 2025, and adjusted net income of $2,079 million ($11.75 per diluted share) versus $459 million ($2.44) a year earlier. Results were driven by the Refining segment, where income before interest and taxes rose to $2,435 million from $476 million on tight transportation fuel supply and elevated crack spreads, while Lubricants & Specialties income fell to $38 million from $52 million and Midstream income declined to $87 million from $98 million; the company also took $109 million of Mississauga Refinery retirement charges and announced a regular $0.525 quarterly dividend alongside a planned separation of its Lubricants & Specialties segment.

• · Adjusted refinery gross margin was $54.22 per produced barrel sold, up 183% from $19.16, driven by tight transportation fuel supply, elevated crack spreads and small refinery RINs waivers from the EPA
• · Crude charge fell to 614,060 BPD from 639,050 BPD, reflecting the planned turnaround at the El Dorado refinery that also reduced Mid-Continent sales
• · Renewables Adjusted EBITDA excluding a $30M LCM inventory benefit was $109M versus $(13)M, aided by improved RINs prices and higher Producer's Tax Credit benefits
• · Lubricants & Specialties segment income fell 26.9% despite Adjusted EBITDA of $174M, because of $109M in Mississauga Refinery retirement charges ($27M impairment, $28M severance, $54M accelerated D&A)
• · Mississauga Refinery retirement is expected to be substantially completed in the second half of 2027
• · Midstream segment income declined 11.2% and Adjusted EBITDA was $101M versus $114M EBITDA in Q3 2025
• · Cash and cash equivalents rose $2,355M from December 31, 2025 to $3,333M at September 30, 2026
• · Net cash provided by operations was $1,784M in Q3 2026; consolidated debt was $2,774M at quarter end
• · Board declared a $0.525 per share quarterly dividend payable December 2, 2026 to holders of record November 12, 2026
• · Planned Separation to distribute at least 80.1% of Lubricants & Specialties stock, substantially completed over 2027

28-10-2026

Parsons Corporation (NYSE: PSN) announced that Executive Vice President and Chief Financial Officer Matt Ofilos will resign effective November 6, 2026, to pursue another professional opportunity, with the resignation not stemming from any disagreement with the company. Board member and former CFO George Ball (CFO from 2008 to 2022) was appointed Interim Chief Financial Officer effective the same date while the Board conducts a search for a permanent successor. The announcement was issued alongside third-quarter 2026 results that were strong, with fiscal year 2026 revenue and adjusted EBITDA guidance midpoints reaffirmed and ranges narrowed, and operating cash flow guidance reiterated.

• · Ofilos' resignation is effective November 6, 2026, and Ball's interim appointment takes effect the same day.
• · Ofilos' resignation is explicitly stated not to result from any disagreement with the company on operations, policies, or practices.
• · Ball joined Parsons in 1995 and held multiple financial and operational leadership positions before becoming CFO; he also helped lead the 2019 IPO.
• · The Board has initiated a thorough search for a permanent CFO successor; no timeline was disclosed.
• · The Q3 2026 earnings release reaffirmed the FY2026 revenue and adjusted EBITDA guidance midpoints and narrowed the ranges; operating cash flow guidance was reiterated.

28-10-2026

Etsy's Q3 2026 shareholder letter, furnished under Item 2.02, reports Etsy Marketplace GMS of $2.6B (up 8.8% Y/Y, 9.1% currency-neutral) and marketplace revenue of $692M (up 10.9% Y/Y), with take rate at 26.2% (+50 bps Y/Y) and adjusted EBITDA of $210M (30.4% margin). The company completed the sale of Depop on July 30, 2026, presented as a discontinued operation. Growth is accelerating, though the letter attributes part of the top-line strength to external GMS tailwinds and does not provide a comparable Y/Y figure for total net income in the excerpt provided.

• · Active buyers grew Y/Y for the first time in two years
• · Active seller base grew at its fastest rate in two years
• · GMS growth accelerated for the sixth consecutive quarter sequentially
• · Depop sale closed July 30, 2026; Etsy results presented on a continuing operations basis

28-10-2026

FuelCell Energy appointed Peter Hopper, co-founder and managing director of Primary Digital Infrastructure and former managing director at DigitalBridge, to its board of directors on October 28, 2026, as the company advances its data center power strategy. Hopper brings more than 25 years of experience and has led or advised on more than $40 billion in acquisitions, capital formation, recapitalizations and strategic investments. The filing is a board appointment announcement with no financial results or guidance disclosed.

• · Hopper will serve on the Nominating, Governance & Sustainability and Compensation and Leadership Development Committees
• · Hopper currently sits on the board of flyExclusive, Inc., serving on its audit and compensation committees
• · Hopper previously co-founded and was CEO of DH Capital, and was a partner at ABRY Partners
• · Company cites data center customers seeking time-to-power, reliability and infrastructure solutions as a driver of the appointment

28-10-2026

ABM Industries Incorporated disclosed that Rene Jacobsen, Executive Vice President and Chief Operating Officer, has given notice of his voluntary retirement effective February 1, 2027. He will transition to the role of Executive Advisor effective November 1, 2026, through February 1, 2027. The filing contains no financial results or quantitative performance data.

• · Retirement notice dated October 28, 2026; Jacobsen's retirement becomes effective February 1, 2027
• · Jacobsen's COO role ends effective November 1, 2026, when he moves to Executive Advisor for the remainder of the transition period

28-10-2026

Nextpower (NXT) reported record Q2 FY27 revenue of $1,109 million (up 22.5% YoY from $905 million) and record bookings, with backlog above $6 billion, and raised FY27 outlook. However, GAAP gross margin compressed to 31.1% from 35.9% in Q1 and 32.4% a year earlier, GAAP net income was flat sequentially at $165 million (up 12.6% YoY), and GAAP diluted EPS was $1.08 versus $1.07 in Q1. The company also completed the ~€230 million Zimmermann PV-Steel acquisition and announced two new board members.

• · Q2 FY27 GAAP gross margin fell to 31.1% from 35.9% in Q1, a 4.8-point sequential decline not explained in the headline.
• · Q2 FY27 GAAP diluted EPS was essentially flat sequentially ($1.08 vs $1.07), and adjusted EBITDA margin declined 2.4 points QoQ to 22.5%.
• · Adjusted EBITDA margin fell YoY from 24.7% to 22.5%, despite revenue growth.
• · Q2 FY27 results include approximately $99 million of IRA 45X credits and tariffs, net (vs $67 million in Q2 FY26), a material contributor to reported profitability.
• · Operating cash flow was $158 million in Q2, with adjusted free cash flow of approximately $135 million per CFO commentary.
• · Cash of about $1.03 billion with no debt, while accounts receivable rose to $584.3M from $417.0M at fiscal year-end and deferred revenue rose to $413.8M from $307.5M.
• · Updated FY27 outlook raised revenue to $4.2-4.45B (from $4.1-4.4B) and adjusted diluted EPS to $4.61-4.87 (from $4.42-4.73).
• · Board appointments of Sarah Slusser and Michael Alvarez were announced in the earnings release (Item 5.02).

28-10-2026

Align Technology announced a CEO succession plan: Jennifer L. Davis, former CEO of Procter & Gamble's Global Healthcare business, will become President and CEO effective December 31, 2026, succeeding Joseph M. Hogan, who has led the company since 2015. Davis joins as CEO-elect and a Board member on November 2, 2026, and Hogan will retire from the Board following the June 16, 2027 strategy meeting. The announcement is positive in tone, though it marks a leadership transition at a company whose separately released Q3 2026 results were issued the same day and whose performance figures are not included in this filing.

• · Davis joins as CEO-elect and a Board member on November 2, 2026, before assuming the CEO role on December 31, 2026
• · Hogan retires from the Board after the strategy meeting on June 16, 2027
• · Davis previously led Procter & Gamble's Global Healthcare business, covering oral-health and personal-health brands across a multibillion-dollar portfolio
• · Q3 2026 financial results were released separately the same day, with a conference call at 4:30 p.m. EDT on October 28, 2026
• · Filing references Align's 10-K for FY2025 (filed February 27, 2026) and 10-Q for Q2 2026 (filed August 5, 2026) for risk factors

28-10-2026

Q2 Holdings (NYSE: QTWO) announced that its Board appointed CFO Jonathan Price as Co-Chief Executive Officer effective October 29, 2026, serving alongside Matt Flake, who continues as President and Chairman. Price also joins the Board of Directors and will remain CFO while the company searches for a successor. Management frames the co-CEO structure as ensuring long-term continuity of the company's financial discipline and growth strategy.

• · Price has served as CFO since November 2024 and joined Q2 in 2018, previously as EVP, Strategy & Emerging Businesses
• · Appointment is effective October 29, 2026
• · Price will remain CFO during the search for a successor, so the CFO role is not yet vacated
• · Company cites margin expansion, balance sheet strengthening, and sharpened capital allocation over the past few years

28-10-2026

Ecovyst Inc. (ECVT) filed an 8-K disclosing that on October 22, 2026, its Compensation Committee approved a Second Amended and Restated Ecovyst Catalyst Technologies LLC Severance Plan, effective the same day. The amended plan increases severance for executive officers: 52 weeks of Compensation outside a Change in Control Protection Period (104 weeks for the CEO), and during the Change in Control Protection Period the greater of that amount or 18 months of Compensation (30 months for the CEO), paid in a lump sum. The filing does not report any departure, appointment, or change in an officer's title.

• · The Prior Plan was the Amended and Restated Ecovyst Catalyst Technologies LLC Severance Plan effective January 1, 2022
• · Severance is paid in a lump sum
• · Officers receive the greater of the individual agreement or Severance Plan benefits where both exist
• · The Severance Plan is filed as Exhibit 10.1

28-10-2026

Modular Medical, Inc. (MODD) held its fiscal 2027 annual shareholder meeting on October 23, 2026, with quorum representing approximately 65% of outstanding shares. All six director nominees were elected, and the 2017 Equity Incentive Plan amendment adding 2,500,000 shares and the ratification of Farber Hass Hurley LLP as auditor were approved. Director Duane DeSisto resigned from the board effective immediately on October 26, 2026, not due to any disagreement with the Company; he had received the highest 'For' vote count of any nominee (3,091,438) but resigned after the election. Voting support was mixed, with Ellen O'Connor Vos receiving only 2,053,232 For votes against 1,065,190 Against.

• · Proposal 2 (equity plan amendment) received 811,943 Against votes and 20,009 Abstain votes, a notably higher opposition level than the auditor ratification
• · Director nominee support ranged from 2,053,232 For (Ellen O'Connor Vos) to 3,091,438 For (DeSisto), with Vos drawing roughly one-third opposition
• · Definitive proxy statement was filed October 1, 2026, and the annual meeting was the fiscal 2027 annual meeting
• · Filing describes DeSisto's resignation as effective immediately and not due to any disagreement with the Company

28-10-2026

Regional Management Corp. reported Q3 2026 net income of $15.1 million and diluted EPS of $1.61, up 5.3% and 13.4% year-over-year, with record total revenue of $178.8 million (up 8.0%). However, the net credit loss rate rose 70 basis points year-over-year to 10.9%, 30+ day delinquencies climbed 50 basis points to 7.5%, and small loan receivables declined 13.5%. The company also announced Liz Canini will join in early November as Chief Credit Risk Officer and declared a $0.30 Q4 dividend.

• · Small loan originations fell 21.9% YoY, reflecting tighter underwriting in higher-risk segments
• · Interest and fee yield declined 100 bps YoY to 28.7%, driven by mix shift toward lower-yielding larger and auto-secured loans and pricing changes
• · The year-over-year credit loss increase was concentrated in 2025-originated loans, with the digital affiliate channel the largest driver
• · Available liquidity declined to $104.0M; funded debt-to-equity ratio 4.6:1.0, funded debt-to-tangible equity 5.1:1.0
• · Company expects substantially all branches under the bank partnership by end of 2027 and cites strong bottom-line growth in 2027
• · Liz Canini joins in early November as Chief Credit Risk Officer; full rollout of the new origination scorecard expected in Q4 2026
• · Q4 2026 dividend of $0.30 per share payable December 16, 2026 to holders of record November 18, 2026

28-10-2026

Churchill Downs Incorporated (Nasdaq: CHDN) appointed Michael Tucker, Founder and Managing Partner of Orvieto Partners, L.P., to its Board of Directors as a Class II Director, with a term expiring at the 2028 Annual Meeting of Shareholders. The appointment expands the Board to eight members. The filing contains no quantitative financial results or period-over-period performance data.

• · Tucker holds a CFA and an MBA from Boston College's Carroll School of Management, plus a B.S. in Finance from Providence College
• · Tucker previously served as Partner and Portfolio Manager at PAR Capital Management, Andover Capital Advisors, LLC, and Standish Mellon Asset Management before founding Orvieto Partners in 2021
• · Tucker's term expires with the other Class II Directors at the 2028 Annual Meeting of Shareholders

28-10-2026

Garrett Motion Inc. announced that Steven Tesoriere, a board designee of funds affiliated with Oaktree Capital Management, has resigned from its Board of Directors, effective upon announcement, along with his service on the Talent Management and Compensation Committee. The filing contains no financial results, guidance, or quantitative performance data, and the company provided no replacement or successor information.

• · Mr. Tesoriere joined the Board in April 2021 as an Oaktree designee under the Series A Investor Rights Agreement
• · He previously chaired the Finance Committee and the Nominating and Governance Committee
• · His departure is tied to an Oaktree designee seat, which may reduce Oaktree's board representation; the filing does not say whether Oaktree retains other designees

28-10-2026

LENZ Therapeutics reported Q3 2026 VIZZ product sales of $2.6 million, up approximately 50% over Q2 2026, on over 38,000 paid prescriptions, while net loss widened to $31.0 million ($0.99 per share) from $16.7 million ($0.59 per share) a year earlier and nine-month SG&A rose to $120.2 million from $51.5 million. The company also announced a strategic reorganization targeting more than 50% reduction in projected 2027 operating expenses (to roughly $70–75 million excluding stock-based compensation), with about $5 million in one-time restructuring charges, and CEO Eef Schimmelpennink will step down effective December 1, 2026, with CFO Dan Chevallard becoming Interim President and CEO. Results are mixed: sales momentum and prescriber growth contrast with rising losses, a 100% decline in R&D spending year-over-year, and lower license revenue versus the prior-year period.

• · Q3 2026 product sales of $2.6M were up approximately 50% over Q2 2026, with paid prescriptions up 51% to over 38,000.
• · Telehealth channel contributed more than 50% of incremental prescriptions in Q3 2026 over Q2 2026.
• · Projected 2027 operating expenses target of $70–75M (excluding stock-based compensation) implies a reduction of over 50%.
• · Estimated one-time net restructuring charges of approximately $5M, with substantially all activities completed in Q4 2026.
• · Cash, cash equivalents and marketable securities of $197.3M as of September 30, 2026.
• · Q3 2026 cost of sales included non-recurring events related to a manufacturing process transition.
• · Net loss per share widened to $0.99 (Q3 2026) from $0.59 and to $3.33 (nine months) from $1.65.
• · Eef Schimmelpennink will remain as a strategic advisor to the Company into 2027.
• · Q3 2026 license revenue included a portion of the upfront payment under the Arrotex license agreement.
• · Nine-month 2026 license revenue included a $2.5M Théa regulatory milestone, $1.25M Everest sublicense revenue, and the Lunatus upfront payment.

28-10-2026

LiveRamp Holdings, Inc. disclosed under Item 5.02 that on October 22, 2026 it entered into an agreement with Vihan Sharma regarding his historic accrued vacation time. The company agreed to pay Mr. Sharma approximately €600,000, and in exchange Mr. Sharma released all related claims against the company. The filing does not state whether Mr. Sharma is departing or changing role.

• · The agreement is dated October 22, 2026, and the 8-K was filed October 28, 2026
• · The filing is made under Item 5.02, which covers officer departures, appointments, and compensatory arrangements, so Mr. Sharma is an officer covered by that item
• · The filing does not specify whether the payment is a severance arrangement or a settlement of a vacation accrual dispute

28-10-2026

Adial Pharmaceuticals, Inc. (ADIL) changed its corporate name to Azora Therapeutics, Inc., with common stock expected to trade on Nasdaq under the ticker "AZR" starting October 29, 2026. Stockholders approved conversion of Series A preferred stock issued in the June 2026 Azora acquisition, and a new executive team was appointed, led by CEO Matt Davidson, Ph.D. and Chief Strategy Officer Julie Saiki, Ph.D., to advance lead asset AT177 (oral, colon-targeted AhR agonist) toward a Phase 1 ulcerative colitis trial in the first half of 2027. The company reports approximately $32 million in gross proceeds from its June 2026 private placement, with cash expected to fund operations into 2028 and a potential additional $32 million tied to Phase 1 initiation.

• · New ticker "AZR" on The Nasdaq Capital Market effective October 29, 2026
• · Series A preferred stock from June 2026 Azora acquisition will automatically convert into common stock, subject to holder-specific beneficial ownership limits
• · Stockholders approved exercise of prefunded warrants sold in the concurrent private placement
• · Azora's new executive team includes a consulting (not full-time) Chief Medical Officer
• · Filing does not disclose executive compensation terms or any material risks specific to the leadership changes beyond the forward-looking statement caveats

28-10-2026

Compass Minerals (CMP) disclosed that Chief Accounting Officer Ashley Ward resigned effective October 23, 2026, with the company stating her departure was not due to any disagreement on operations, policies, or practices. On October 28, 2026, the company appointed Brett Teuscher, a 44-year-old internal audit leader who joined in May 2026, as its new Chief Accounting Officer at a $300,000 base salary, a 40% targeted bonus, and a $115,000 annual LTI target.

• · Ward's resignation was effective October 23, 2026, one day after it was announced on October 22, 2026
• · Teuscher previously served at BlueScope from January 2020 to May 2026, ultimately as Director of Finance Transformation, ERM and Procurement
• · Teuscher holds an MBA and a Bachelor of Science in Accounting from Utah State University
• · Teuscher has no family relationships with directors or executive officers and no Item 404(a) related-person transactions were reported
• · Employment is at will under the Offer Letter, filed as Exhibit 10.1

28-10-2026

Radian Group Inc. (NYSE: RDN) announced that its Board of Directors appointed Daniel Kobell as Senior Executive Vice President and Chief Financial Officer, effective October 28, 2026. Mr. Kobell had already served as Interim Chief Financial Officer since February 12, 2026, so the action formalizes a permanent appointment rather than introducing a new executive. The filing discloses no financial results, compensation terms, or performance metrics.

• · Mr. Kobell has served as Interim Chief Financial Officer since February 12, 2026
• · Professional biography is incorporated by reference to the 'Executive Officers' section of the 2026 Proxy Statement filed April 2, 2026
• · Filing discloses no compensatory arrangements for Mr. Kobell in this report

28-10-2026

Bausch + Lomb director Nathalie Bernier resigned from the Board of Directors and the Science and Technology Committee effective October 28, 2026, in connection with a general mutual release of certain claims. The company will pay her prorated cash compensation and fully accelerate vesting of her unvested 2026 restricted share unit awards, and the Board does not intend to fill the vacancy. The filing states the resignation was not due to any disagreement with the company on operations, policies, or practices.

• · Board vacancy will not be filled, reducing Board size by one seat
• · Accelerated full vesting of 2026 annual grant RSUs as part of the separation terms
• · Resignation was stated to be unrelated to any disagreement on company operations, policies, or practices

28-10-2026

Monroe Federal Bancorp, Inc. (MFBI) announced that President and CEO Lewis R. Renollet retired effective October 26, 2026, and was succeeded by Charles G. Brown III (age 60), who has over 40 years of banking experience. Renollet remains on the Boards and as Senior Executive Vice President through December 31, 2026, with his base salary reduced to $120,000 per year, while Brown's employment agreement sets a base salary of $215,000 plus change-in-control protections.

• · Renollet's employment automatically terminates December 31, 2026, but he continues as a director
• · Brown's severance on a non-change-in-control termination includes remaining-term salary and bonus, a lump-sum DC plan contribution, and medical coverage, conditioned on a release of claims
• · Brown's change-in-control severance is a lump sum of 3x highest base salary plus highest bonus from the prior three fiscal years, with 36 months of benefits
• · Brown's employment agreement initial term runs through December 31, 2026, then renews annually from January 1, 2027, subject to Board approval
• · Renollet's amendment states the changes do not constitute Good Reason under his employment agreement
• · Brown has no family relationships with directors or officers and no Item 404(a) related-party transactions

28-10-2026

Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, effective October 28, 2026, with her also serving as principal financial officer and principal accounting officer. Her employment agreement sets a $275,000 annual base salary, a 35% target bonus, an option to purchase 130,000 shares under the 2022 Equity Incentive Plan, and severance of six months' base salary (twelve months plus enhanced benefits and full equity acceleration on a change of control). The filing does not disclose any financial performance metrics.

• · Weidner's prior role at Senseonics ran from March 2025 to October 2026, a consultancy focused on financial reporting and operational accounting
• · Weidner previously served as VP Finance at OncoC4, Inc. (March 2021 to January 2025), where she built the finance function through Phase III clinical trials
• · Severance eligibility begins three months after the Effective Date, and the option vests over four years with 25% at the one-year anniversary

28-10-2026

BRC Group Holdings, Inc. (formerly B. Riley Financial, Inc.) disclosed that its indirect subsidiary BRSH Merger Sub LLC completed a short-form merger with B. Riley Securities Holdings, Inc. (BRSH) effective October 22, 2026, after owning more than 90% of BRSH common stock. Remaining BRSH public holders receive $8.88 per share in cash, and BRSH restricted stock awards are substituted with BRC restricted stock awards at a 2:1 ratio. Andy Moore, a former BRC named executive officer (until September 18, 2025) and BRSH director, received a Substitute Restricted Stock Award covering 374,720 BRC shares.

• · Effective Time of the Short-Form Merger was October 22, 2026, upon filing of the Certificate of Ownership and Merger with the Delaware Secretary of State
• · Substitute awards retain the original vesting terms and schedule, including any acceleration, and the Vesting Commencement Date of March 10, 2025 is carried over
• · Unvested substitute restricted shares are forfeited upon termination of employment for any reason, including death, disability, with or without cause
• · Grant Date of the substitute awards is October 22, 2026; the filing includes the form of award agreement as Exhibit 10.1 with grantee-specific fields left blank
• · Filing lists the registrant's address as Los Angeles, CA, and reports the Company's principal executive offices telephone as (310) 966-1444 while the EDGAR header shows 818-884-3737

28-10-2026

Tronox Holdings plc's Board of Directors approved the appointment of Yasser Al-Daajani as a new board member on October 27, 2026, effective the same day. He was nominated by Cristal International Holdings B.V. under the 2019 Shareholders Agreement and currently serves as Executive Vice President, Petrochemicals at Tasnee. The filing discloses no material financial results, and the director's compensation is standard for non-employee directors.

• · Al-Daajani has more than 25 years of petrochemicals experience and holds a B.S. in Chemical Engineering from King Fahd University of Petroleum & Minerals
• · Appointment was made under the Shareholders Agreement dated April 10, 2019 among Tronox, Cristal and other parties
• · No related party transactions or selection arrangements with other persons were disclosed under Item 404(a) of Regulation S-K
• · Filing includes Inline XBRL cover page exhibit (Exhibit 104); no financial statements were included

28-10-2026

ConnectM Technology Solutions (OTCQX: CNTM) announced the appointment of Leonardo ("Leo") Riera to its Board of Directors as Lead Independent Director, effective October 21, 2026, expanding the Board from five to six members. Riera brings more than 40 years of investment banking and capital markets experience, including roughly a decade as Country Head of Bankers Trust in Venezuela, and will also serve on the Audit and Compensation Committees and chair the Nominating and Corporate Governance Committee. The filing contains no quantitative financial results, so it offers no period-over-period performance comparison; the Company's own forward-looking statements flag a going concern explanatory paragraph, a pending exchange listing application, and a contemplated divestiture of its Owned Service Network operations.

• · Riera will preside over sessions of independent directors and serve as their principal liaison to the Chairman
• · Riera is currently Audit Committee Chair at Katmai Tech and FenixOro Gold and previously chaired Sidus Space
• · Riera co-founded EnviroPower Renewable and served as its Chairman and CEO from 2012 to 2018, raising all of its development capital
• · The filing discloses a going concern explanatory paragraph and that the value of the Blue Cloud shareholding is subject to a lock-up and may fluctuate significantly
• · The Company is evaluating distributed compute as an asset-light alternative to traditional data centers

28-10-2026

Gevo, Inc. (NASDAQ: GEVO) announced that K'Lynne Johnson, founder and former CEO of Elevance Renewable Sciences, will join its Board of Directors effective November 4, 2026. The appointment brings over three decades of innovation, R&D, manufacturing, and executive experience to the board, and is framed by management as supporting Gevo's next phase of growth. The filing contains no financial results or quantitative performance metrics.

• · Johnson currently sits on the boards of FMC Corporation, Trinseo PLC, J.M. Huber Corporation, and BlueScope Steel Limited, and is independent board chair of DMC Biotechnologies
• · Gevo owns an ethanol plant with adjacent carbon capture and storage facility and a Class VI carbon-storage well, plus one of the largest dairy-based RNG facilities in the U.S.
• · Gevo's specialty ATJ facility has been operating since 2012

28-10-2026

Vir Biotechnology's Board of Directors approved an increase in board size from eight to nine members and appointed Suzanne Topalian, M.D., to fill the newly created Class III seat, effective October 27, 2026, with a term through the 2028 annual meeting. Dr. Topalian was also appointed to the Science and Technology Committee and receives standard non-employee director compensation, including automatic option and RSU grants under the 2019 Equity Incentive Plan.

• · Dr. Topalian was appointed to the Science and Technology Committee of the Board
• · Dr. Topalian was granted stock option and restricted stock unit awards on her appointment date under the automatic grant program
• · The Company entered into its standard form indemnity agreement with Dr. Topalian
• · No related party transactions requiring disclosure under Item 404(a) of Regulation S-K were identified

28-10-2026

Dropbox announced that preliminary Q3 2026 results are expected to be in line with or above guidance for revenue, constant currency revenue, and non-GAAP operating margin, with full results due November 5, 2026. The company also disclosed a reduction in global workforce of approximately 9%, with estimated cash expenditures of $27 million to $33 million and incremental expense of $20 million to $25 million, mostly recognized in Q4 2026. CTO Ali Dasdan will step down effective November 18, 2026, receiving a $515,000 pro rata bonus and a lump sum of approximately $1.3 million under a separation agreement.

• · Q3 2026 results were preliminary and unaudited, subject to quarter-end closing and accounting review
• · Q3 2026 earnings release scheduled for Thursday, November 5, 2026
• · Guidance was previously provided in an investor supplement posted August 6, 2026
• · Company accrued compensation expense through September 30, 2026 for a portion of annual bonuses
• · Majority of workforce reduction cash payments expected in Q4 2026, remainder in 2027
• · Dasdan's separation agreement will be filed as an exhibit to a subsequent periodic report
• · Forward-looking statements flag risk that reduction costs may exceed estimates or be incurred on a different timeline

28-10-2026

T-Mobile US, Inc. (TMUS) disclosed that G. Michael Sievert notified the Board on October 26, 2026 of his decision to resign from the Board and its Transaction Committee, and to cease serving as Vice Chair, effective November 1, 2026. The resignation coincides with the expiration of a September 19, 2025 amendment to his Amended and Restated Employment Agreement dated March 9, 2023. The company states the resignation is not the result of any disagreement on operations, policies, or practices.

• · Sievert's resignation from the Board and Transaction Committee and his cessation as Vice Chair take effect November 1, 2026
• · Resignation is tied to expiration of the September 19, 2025 employment agreement amendment
• · Filing expressly states no disagreement with the company led to the departure

28-10-2026

Arcutis Biotherapeutics appointed Rob Scott, MD, a former AbbVie Chief Medical Officer and Amgen global development leader, to its Board of Directors effective October 23, 2026, as disclosed in an 8-K filed October 28, 2026. The company describes ZORYVE adoption as strong and points to a growing pipeline of potential new ZORYVE indications and a novel biologic. The filing contains no quantitative financial results, guidance, or period-over-period metrics.

• · Dr. Scott is a Zimbabwean-born physician and graduate of the University of Cape Town
• · Dr. Scott previously helped develop Lipitor and Norvasc at Pfizer and the first commercially available polypill, Caduet
• · Dr. Scott has sat on multiple public and private boards and scientific and strategic advisory boards
• · ZORYVE is indicated for atopic dermatitis (ages 2 and older for the 0.05% cream, 6 and older for the 0.15% cream), plaque psoriasis (cream and foam), and seborrheic dermatitis (foam, ages 9 and older)
• · Appointment was effective October 23, 2026, five days before the October 28, 2026 announcement
• · The filing lists Items 5.02, 7.01, and 9.01; the press release is furnished as Exhibit 99.1

28-10-2026

ManpowerGroup announced that Lidia Fonseca, former Executive Vice President and Chief Digital and Technology Officer at Pfizer, will join its Board of Directors effective November 1, 2026. Fonseca led Pfizer's enterprise AI, digital, data and technology strategy from January 2019 to April 2026 and currently serves as Senior Advisor to Pfizer's CEO and on the board of Medtronic plc. The announcement is a governance and board-composition update with no quantitative financial disclosure.

• · Fonseca spent a decade in diagnostics as SVP and Chief Information Officer at Quest Diagnostics and earlier at LabCorp
• · Fonseca holds a bachelor's degree from UC Berkeley and an MBA and Master of Business Informatics from Rotterdam School of Management, Erasmus University
• · Fonseca built Pfizer's enterprise AI program from inception and scaled it across the enterprise, per the company release

28-10-2026

First Financial Bancorp (Nasdaq: FFBC) appointed Timothy A. Massa as a new director, effective immediately, after the Board voted on October 27, 2026 to increase its size from 10 to 11 members. The appointment followed a recommendation from the Corporate Governance and Nominating Committee, and the company cited Massa's human capital and executive leadership experience. The filing contains no performance figures, so there is no period-over-period comparison to balance.

• · Massa retired from Kroger in September 2026 after 12 years as executive vice president and chief associate experience officer, and currently serves as a strategic advisor to Kroger
• · First Financial Bank received its second consecutive Outstanding Community Reinvestment Act rating from the Federal Reserve in 2025
• · Massa's expertise includes executive compensation, CEO succession planning, talent strategy, labor relations, and M&A integrations